Colchicine/ropivacaine - PK MED
Alternative Names: PKM-01Latest Information Update: 19 May 2025
At a glance
- Originator PK MED
- Class Anilides; Anti-ischaemics; Antigouts; Antineoplastics; Antirheumatics; Colchicum alkaloids; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules; Vascular disorder therapies
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gout
Most Recent Events
- 14 Nov 2024 Pharmacodynamics data from preclinical studies in Gout flares presented at the ACR Convergence 2024
- 27 May 2024 Colchicine/ropivacaine - PK-MED is available for licensing as of 27 May 2024. https://www.pk-med.com/partnering (PK MED pipeline, May 2024)
- 26 Feb 2024 Preclinical trials in Gout in France (Intra-articular), prior to February 2024